Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Monday, Bernstein analysts adjusted their outlook on Avantor Inc . (NYSE:AVTR) shares, lowering the price target to $15.00 from the previous $18.00 while maintaining a Market Perform rating. The stock, which has declined nearly 14% in the past week and 39% year-to-date according to InvestingPro data, faced pressure following disappointing first-quarter results that fell short of expectations.
Avantor’s recent earnings report revealed challenges, including increased competitive intensity within the market. This competition has led to a loss of business at some accounts, although there have been some wins as well. Management admitted that aggressive pricing strategies by competitors played a role in these shifts, with Thermo Fisher Scientific (NYSE:TMO) notably strengthening its position in the channel, potentially by reducing prices to increase volume and expand market share. Despite these challenges, InvestingPro data shows Avantor maintains a "GOOD" overall financial health score, with particularly strong marks in profitability and relative value metrics.
In their analysis, Bernstein highlighted that while Avantor is facing difficulties, there are some positive developments. The company announced an additional $100 million in cost savings and has introduced new leadership roles, including a CEO and head of the lab segment, which could potentially invigorate the company’s strategy and performance.
Despite these strategic changes, the sentiment from both Bernstein and the market remains cautious. The competitive landscape and Avantor’s response to these challenges will continue to be closely monitored by investors and industry observers alike. The lowered price target reflects Bernstein’s current view of Avantor’s value in light of the recent earnings report and market dynamics.
In other recent news, Avantor Inc. reported its first-quarter 2025 earnings, revealing a revenue of $1.58 billion, which fell short of the anticipated $1.61 billion. The earnings per share were $0.23, aligning with forecasts, but the revenue miss led to a significant drop in the company’s stock. In response, several analyst firms adjusted their outlook on Avantor. RBC Capital Markets reduced its price target to $20 while maintaining an Outperform rating, reflecting optimism about the company’s long-term potential despite current challenges. TD Cowen downgraded Avantor’s stock from Buy to Hold, lowering the price target to $15.50 due to concerns over growth prospects and margin outlook. Morgan Stanley (NYSE:MS) also downgraded the stock to Equalweight with a new price target of $15, citing competitive pressures and potential estimate downside risks. Stifel followed suit by cutting its rating to Hold and slashing the price target to $14, highlighting disappointing first-quarter results and issues in the bioprocess sector. These developments come amid Avantor’s announcement of CEO Michael Stubblefield’s planned departure, adding another layer of uncertainty to the company’s future.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.